1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Legal & IP

Device Settlements Contribute To DoJ's $2.5Bn Health-Care FCA Haul

 
• By Elizabeth Orr

The US Department of Justice collected $2.8bn in settlements and judgments involving violations of the False Claims Act in 2018, including $2.5bn in health-care cases. Key device industry recoveries included $33.2m from Alere, $12.5m from Angiodynamics, and $30m in two separate settlements from Covidien and its subsidiary ev3.

United States Department of Justice headquarter building in Washington D.C.
US Department of Justice

The devices and diagnostics industries contributed at least $86.1m in settlements to the US Department of Justice’s fiscal 2018 False Claims Act haul of $2.8bn, data released by the agency shows.

Of the overall $2.8bn, $2.5bn came from the health-care industry, including settlements from drug and device manufacturers, insurers, health care...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

Former Top OIG Attorney Gives Inside Look At Fraud Prevention

 
• By Elizabeth Orr

Former HHS-OIG attorney Rob DeConti emphasized the significance of data analytics and compliance in combating healthcare fraud, urging medical tech companies to adopt robust measures to prevent potential risks.

DME And Diagnostics In Crosshairs As DOJ ‘Follows The Money’

 
• By Elizabeth Orr

The DOJ has launched nearly 70 enforcement actions in 2025, targeting diagnostics, durable medical equipment, and telehealth fraud. Key cases involve significant fraudulent claims against Medicare, with individuals facing severe penalties.

Mexico’s New Procurement Rules Aim To Increase Healthcare Investment, But May Face Legal Trouble

 
• By Francesca Bruce

Legal experts warn, however, that new Mexican procurement rules are discriminatory and could be challenged in the courts.

Innovative Wants Injunction Against J&J Subsidiary After $442M Antitrust Verdict

 
• By Elizabeth Orr

Innovative Healthcare is asking for a permanent injunction against Johnson & Johnson subsidiary Biosense Webster after winning a $442 million antitrust verdict. The injunction aims to prevent continued anticompetitive practices in the electrophysiology catheter market.

More from Policy & Regulation